BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 19608274)

  • 1. Fluorescence in situ hybridization for del(5q) in myelodysplasia/acute myeloid leukemia: comparison of EGR1 vs. CSF1R probes and diagnostic yield over metaphase cytogenetics alone.
    Sun Y; Cook JR
    Leuk Res; 2010 Mar; 34(3):340-3. PubMed ID: 19608274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q-.
    Mallo M; Arenillas L; Espinet B; Salido M; Hernández JM; Lumbreras E; del Rey M; Arranz E; Ramiro S; Font P; González O; Renedo M; Cervera J; Such E; Sanz GF; Luño E; Sanzo C; González M; Calasanz MJ; Mayans J; García-Ballesteros C; Amigo V; Collado R; Oliver I; Carbonell F; Bureo E; Insunza A; Yañez L; Muruzabal MJ; Gómez-Beltrán E; Andreu R; León P; Gómez V; Sanz A; Casasola N; Moreno E; Alegre A; Martín ML; Pedro C; Serrano S; Florensa L; Solé F
    Haematologica; 2008 Jul; 93(7):1001-8. PubMed ID: 18591625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delineation by molecular cytogenetics of 5q deletion breakpoints in myelodyplastic syndromes and acute myeloid leukemia.
    Royer-Pokora B; Trost D; Müller N; Hildebrandt B; Germing U; Beier M
    Cancer Genet Cytogenet; 2006 May; 167(1):66-9. PubMed ID: 16682289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytogenetic features of 5q deletion and 5q- syndrome in myelodysplastic syndrome in Korea; marker chromosomes proved to be chromosome 5 with interstitial deletion by fluorescence in situ hybridization.
    Lee HR; Oh B; Hong DS; Zang DY; Yoon HJ; Kim HJ; Kim I; Ahn JS; Cheong JW; Lee KA; Cho KS; Lee MH; Bang SM; Kim TY; Yun YM; Min YH; Lee YK; Lee DS;
    Cancer Genet Cytogenet; 2010 Dec; 203(2):193-202. PubMed ID: 21156233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic screening at diagnosis of -5/del(5)(q31), -7, or chromosome 8 aneuploidy by interphase fluorescence in situ hybridization in 110 acute myelocytic leukemia and high-risk myelodysplastic syndrome patients: concordances and discrepancies with conventional cytogenetics.
    Beyer V; Castagné C; Mühlematter D; Parlier V; Gmür J; Hess U; Kovacsovics T; Meyer-Monard S; Tichelli A; Tobler A; Jacky E; Schanz U; Bargetzi M; Hagemeijer A; de Witte T; van Melle G; Jotterand M
    Cancer Genet Cytogenet; 2004 Jul; 152(1):29-41. PubMed ID: 15193439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Redefining monosomy 5 by molecular cytogenetics in 23 patients with MDS/AML.
    Herry A; Douet-Guilbert N; Morel F; Le Bris MJ; De Braekeleer M
    Eur J Haematol; 2007 Jun; 78(6):457-67. PubMed ID: 17391336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Submicroscopic deletions in 5q- associated malignancies.
    Crescenzi B; La Starza R; Romoli S; Beacci D; Matteucci C; Barba G; Aventin A; Marynen P; Ciolli S; Nozzoli C; Martelli MF; Mecucci C
    Haematologica; 2004 Mar; 89(3):281-5. PubMed ID: 15020265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does monosomy 5 really exist in myelodysplastic syndromes and acute myeloid leukemia?
    Galván AB; Mallo M; Arenillas L; Salido M; Espinet B; Pedro C; Florensa L; Serrano S; Solé F
    Leuk Res; 2010 Sep; 34(9):1242-5. PubMed ID: 20362335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interphase FISH does not improve the detection of DEL(5q) and DEL(20q) in myelodysplastic syndromes.
    Douet-Guilbert N; Herry A; LE Bris MJ; Guéganic N; Bovo C; Morel F; DE Braekeleer M
    Anticancer Res; 2011 Mar; 31(3):1007-10. PubMed ID: 21498729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion.
    Sebaa A; Ades L; Baran-Marzack F; Mozziconacci MJ; Penther D; Dobbelstein S; Stamatoullas A; Récher C; Prebet T; Moulessehoul S; Fenaux P; Eclache V
    Genes Chromosomes Cancer; 2012 Dec; 51(12):1086-92. PubMed ID: 22933333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluorescence in situ hybridization testing for -5/5q, -7/7q, +8, and del(20q) in primary myelodysplastic syndrome correlates with conventional cytogenetics in the setting of an adequate study.
    Pitchford CW; Hettinga AC; Reichard KK
    Am J Clin Pathol; 2010 Feb; 133(2):260-4. PubMed ID: 20093235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic yield of bone marrow and peripheral blood FISH panel testing in clinically suspected myelodysplastic syndromes and/or acute myeloid leukemia: a prospective analysis of 433 cases.
    Coleman JF; Theil KS; Tubbs RR; Cook JR
    Am J Clin Pathol; 2011 Jun; 135(6):915-20. PubMed ID: 21571964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deletions of chromosome 5 in malignant myeloid disorders.
    Le Beau MM
    Cancer Surv; 1992; 15():143-59. PubMed ID: 1451109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of chromosome 5 aberrations in complex karyotypes of patients with myeloid disorders reveals their contribution to dicentric and tricentric chromosomes, resulting in the loss of critical 5q regions.
    Herry A; Douet-Guilbert N; Morel F; Le Bris MJ; Morice P; Abgrall JF; Berthou C; De Braekeleer M
    Cancer Genet Cytogenet; 2007 Jun; 175(2):125-31. PubMed ID: 17556068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular cytogenetic profiling of complex karyotypes in primary myelodysplastic syndromes and acute myeloid leukemia.
    Trost D; Hildebrandt B; Beier M; Müller N; Germing U; Royer-Pokora B
    Cancer Genet Cytogenet; 2006 Feb; 165(1):51-63. PubMed ID: 16490597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Several chromosomes involved in translocations with chromosome 5 shown with fluorescence in situ hybridization in patients with malignant myeloid disorders.
    Bram S; Rödjer S; Swolin B
    Cancer Genet Cytogenet; 2004 Nov; 155(1):74-8. PubMed ID: 15527906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation.
    Liu TX; Becker MW; Jelinek J; Wu WS; Deng M; Mikhalkevich N; Hsu K; Bloomfield CD; Stone RM; DeAngelo DJ; Galinsky IA; Issa JP; Clarke MF; Look AT
    Nat Med; 2007 Jan; 13(1):78-83. PubMed ID: 17159988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myelodysplastic syndromes with del(5q): indications and strategies for cytogenetic testing.
    Haferlach C; Bacher U; Tiu R; Maciejewski JP; List A
    Cancer Genet Cytogenet; 2008 Dec; 187(2):101-11. PubMed ID: 19027491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new recurrent translocation, t(5;11)(q35;p15.5), associated with del(5q) in childhood acute myeloid leukemia. The UK Cancer Cytogenetics Group (UKCCG).
    Jaju RJ; Haas OA; Neat M; Harbott J; Saha V; Boultwood J; Brown JM; Pirc-Danoewinata H; Krings BW; Müller U; Morris SW; Wainscoat JS; Kearney L
    Blood; 1999 Jul; 94(2):773-80. PubMed ID: 10397745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cryptic deletion of EGR1 in association with a novel balanced t(5;22)(q31;q11.2) in a patient with myelodysplastic syndrome.
    Hoffman MW; Janney S; Batanian JR
    Cancer Genet Cytogenet; 2009 Jun; 191(2):106-8. PubMed ID: 19446747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.